BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 10339494)

  • 1. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Roosnek E; Hertenstein B; Schipper RF; Schreuder GM; D'Amaro J; Oudshoorn M; van Biezen JH; Hermans J; Willemze R; Niederwieser D
    Blood; 1999 Jun; 93(11):3863-5. PubMed ID: 10339494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML). Chronic Leukemia Working Party of the European Blood and Marrow Transplant Registry.
    Posthuma EF; Falkenburg JH; Apperley JF; Gratwohl A; Hertenstein B; Schipper RF; Oudshoorn M; Biezen JH; Hermans J; Willemze R; Roosnek E; Niederwieser D
    Leukemia; 2000 May; 14(5):859-62. PubMed ID: 10803518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
    Buzyn A; Ostankovitch M; Zerbib A; Kemula M; Connan F; Varet B; Guillet JG; Choppin J
    Eur J Immunol; 1997 Aug; 27(8):2066-72. PubMed ID: 9295046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific human cellular immunity to bcr-abl oncogene-derived peptides.
    Bocchia M; Korontsvit T; Xu Q; Mackinnon S; Yang SY; Sette A; Scheinberg DA
    Blood; 1996 May; 87(9):3587-92. PubMed ID: 8611681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA CW3 and HLA CW4 have a protective effect on acquisition of chronic myeloid leukemia on Mexican patients.
    Rosas-Cabral A; Irigoyen L; Alvarado L; Vela-Ojeda J; Ayala-Sánchez M; Tripp-Villanueva F; Sánchez E; Gonzalez-Llaven J; Gariglio P
    Rev Invest Clin; 2003; 55(4):423-8. PubMed ID: 14635607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukaemia.
    Norbury LC; Clark RE; Christmas SE
    Br J Haematol; 2000 Jun; 109(3):616-21. PubMed ID: 10886212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
    Yotnda P; Firat H; Garcia-Pons F; Garcia Z; Gourru G; Vernant JP; Lemonnier FA; Leblond V; Langlade-Demoyen P
    J Clin Invest; 1998 May; 101(10):2290-6. PubMed ID: 9593785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
    Bosch GJ; Joosten AM; Kessler JH; Melief CJ; Leeksma OC
    Blood; 1996 Nov; 88(9):3522-7. PubMed ID: 8896419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.
    Rusakiewicz S; Madrigal A; Travers P; Dodi AI
    Cancer Immunol Immunother; 2009 Sep; 58(9):1449-57. PubMed ID: 19360407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
    Clark RE; Dodi IA; Hill SC; Lill JR; Aubert G; Macintyre AR; Rojas J; Bourdon A; Bonner PL; Wang L; Christmas SE; Travers PJ; Creaser CS; Rees RC; Madrigal JA
    Blood; 2001 Nov; 98(10):2887-93. PubMed ID: 11698267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
    Butt NM; Rojas JM; Wang L; Christmas SE; Abu-Eisha HM; Clark RE
    Haematologica; 2005 Oct; 90(10):1315-23. PubMed ID: 16219567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
    Nieda M; Nicol A; Kikuchi A; Kashiwase K; Taylor K; Suzuki K; Tadokoro K; Juji T
    Blood; 1998 Feb; 91(3):977-83. PubMed ID: 9446659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
    Bocchia M; Wentworth PA; Southwood S; Sidney J; McGraw K; Scheinberg DA; Sette A
    Blood; 1995 May; 85(10):2680-4. PubMed ID: 7742526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules.
    Berke Z; Andersen MH; Pedersen M; Fugger L; Zeuthen J; Haurum JS
    Leukemia; 2000 Mar; 14(3):419-26. PubMed ID: 10720136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-ABL-specific T cells can be detected in healthy donors and in chronic myeloid leukemia patients following allogeneic stem cell transplantation.
    Butt NM; Wang L; Abu-Eisha HM; Christmas SE; Clark RE
    Blood; 2004 Apr; 103(8):3245. PubMed ID: 15070713
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunological characterization of the tumor-specific bcr/abl junction of Philadelphia chromosome positive chronic myeloid leukemia.
    Barrett J; Guimaraes A; Cullis J; Goldman JM
    Stem Cells; 1993 Oct; 11 Suppl 3():104-8. PubMed ID: 8298471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human leukocyte antigens in Indian patients with chronic myeloid leukemia.
    Chhaya SU
    Leuk Lymphoma; 2006 Feb; 47(2):291-5. PubMed ID: 16321860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic myeloid leukemia as an immunological target.
    Lim SH; Coleman S
    Am J Hematol; 1997 Jan; 54(1):61-7. PubMed ID: 8980262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
    Wagner WM; Ouyang Q; Pawelec G
    Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
    Zorn E; Orsini E; Wu CJ; Stein B; Chillemi A; Canning C; Alyea EP; Soiffer RJ; Ritz J
    Transplantation; 2001 Apr; 71(8):1131-7. PubMed ID: 11374415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.